Instituto Di Ricovero E Cura A Carattere Scientifico — Clinical Trial Site

21 Registered trials

10 Currently recruiting

Organisation

Instituto Di Ricovero E Cura A Carattere Scientifico

Location

Bologna, Italy

Identifier

ORG-100011217

Address

Via Pilastroni 4, 25125, Italy

Departments

#ITA7:Divisione di Retina Medica
Alzheimer rehabilitation department
Centro per la memoria MAC
IRCCS Istituto de Scienze Neurologiche di Bologna (ISNB)
Nervous System Medical Oncology
Neurologia
Neurology
Neurology Unit
Oncology
Ospedale Bellaria
Ospedale Bellaria U.O.C. Otorinolaringoiatria
Scienze Neurologiche di Bologna (ISNB)
UOC Clinica Neurologica
UOC Neurological Clinic
UOC Oncologia
UOC Oncologia del sistema nervoso
UOC Otorinolaringoiatria

Clinical trials at this site (21)

Search interface

An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Pending

2025-523911-13-00 Narcolepsy Type 1 5
A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting

2023-504478-39-00 Squamous cell carcinoma of head and neck 5 2025-05-23
A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting

2024-513077-48-00 O6-methylguanine methyltransferase (MGMT) unmethylated 5 2024-12-19
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Generalized Myasthenia Gravis 5 2024-11-27
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis Recruiting

2023-507539-40-00 Myasthenia Gravis 4 2024-07-19
Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting

2024-519404-27-00 IDH-mutant grade 2 or 3 astrocytoma 5 2026-01-16
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia Recruiting

2025-520981-23-00 Idiopathic Hypersomnia (IH) 4 2025-08-26
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia Recruiting

2024-519822-18-00 Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia 10 2025-05-14
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Recurrent Meningioma without local treatment options (S 4 2025-03-10
Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting

2023-505267-36-00 Glioblastoma 5 2024-03-15
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting

2022-501822-39-00 Glioblastoma 9 2023-07-31
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-20
A study to test whether BI 764524 helps people with an eye condition called diabetic retinopathy Ended

2023-508891-12-00 Diabetic retinopathy 4 2024-11-28
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended

2024-515452-20-00 Narcolepsy Type 2 4 2025-04-01
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 Ended

2024-511112-24-00 Narcolepsy Type 1 4 2025-01-17
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy. Ended

2023-504892-25-00 Narcolepsy 5 2024-06-14
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) Ended

2023-506873-36-00 Frontotemporal dementia (FTD) 5 2020-06-29
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended

2022-500691-59-00 Alzheimer's disease (AD) 4